Stem cell transplantation for CIDP – pro

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an acquired immune-mediated inflammatory disorder of the peripheral nervous system. The pathologic hallmark of the disease is loss of the myelin sheath (the fatty covering that protects nerve fibers) of the peripheral nerves.
First line treatment for CIDP includes corticosteroids (e.g. prednisone), plasmapheresis (plasma exchange) and intravenous immunoglobulin (IVIg) which may be prescribed alone or in combination with an immunosuppressant drug. IVIG and plasmapheresis have proven benefit in randomized, double-blind, placebo-controlled trials. A nubmer of case reprots, series and some phase II studies establish that amny patients with this condition respond with amelioration of symptoms or with a remission after a high dose therapy regimen with autologous stem cell transplantation.

Toothaker TB, Brannagan TH (2007). “Chronic inflammatory demyelinating polyneuropathies: current treatment strategies”. Curr Neurol Neurosci Rep 7 (1): 63–70

S. Renaud, P. Fuhr, J. Halter, A. Gratwohl, A. Steck(2007) Autologous stem cell transplantation in therapy resistant chronic inflammatory demyelinating disease (CIDP) A phase II study. Call for patients
Clinical Neurophysiology, Volume 118, Issue 2, Pages e4-e5

Oyama, Y., Sufit, R., Loh, Y., Statkute, L., Yaung, K., Quigley, K., Gonda, E., Spahovic, D., Bronesky, D., Burt, R. K.
Neurology 2007 69: 1802-1803

Brannagan, T.H., III, Pradhan, A., Heiman-Patterson, T., Winkelman, A.C., Styler, M.J., Topolsky, D.L., Crilley, P.A., Schwartzman, R.J., Brodsky, I., Gladstone, D.E.
High-dose cyclophosphamide without stem-cell rescue for refractory CIDP
Neurology 2002 58: 1856-1858

H. W Axelson, G. Oberg, and H. Askmark
Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP
BMJ Case Reports, February 2, 2009; 2009

Lehmann, Helmar C., Meyer zu Horste, Gerd, Kieseier, Bernd C., Hartung, Hans-Peter
Review: Pathogenesis and treatment of immune-mediated neuropathies
Therapeutic Advances in Neurological Disorders 2009 2: 261-281

Participate in our Forums

To ask questions or participate in a discussion, please visit our Forums. You must LOGIN to participate.

Help Us Help Others

You can become a Site Sponsor. Or you may wish to support our work with a Donation.

Focused Articles For You

Lay Portal